Navigation Links
New England Journal of Medicine releases study showing GSK's FluLaval Quadrivalent vaccine effective in preventing seasonal flu in children
Date:12/11/2013

;blog(www.morethanmedicine.us.gsk.com/blog/). 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.

[1] Moderately severe influenza was defined as fever greater than 39°C or physician-confirmed acute otitis media or lower respiratory illness (shortness of breath, pulmonary congestion, pneumonia, bronchiolitis, bronchitis, wheezing, croup) or serious extra-pulmonary complication including myositis, encephalitis, seizure, or myocarditis.


'/>"/>
SOURCE GlaxoSmithKline plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New England Laser Options Adds On Professional Hair Removal with the Astanza Liberty IPL System
2. CVS Caremark Uses Data to Combat National Prescription Drug Abuse Epidemic; Program Details Published in New England Journal of Medicine Online
3. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
6. Een studie in het New England Journal of Medicine bevestigt dat universele dekolonisatie van ic-patiënten voor 44% minder bloedstroominfecties zorgt
7. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
8. New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
9. New England Biolabs Releases a New Fast, Low-Nanogram Input Library Prep Method for DNA and RNA Sequencing
10. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
11. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... and SAN DIEGO , July 31, ... company Eisai Co., Ltd. (Headquarters: Tokyo ... and Halozyme Therapeutics, Inc. (Headquarters: San Diego, ... Torley , "NASDAQ: HALO") have signed a clinical collaboration ... ® , "eribulin") in combination with Halozyme,s investigational drug ...
(Date:7/30/2015)... -- Edwards Lifesciences Corporation (NYSE: EW ), the global ... today announced that Robert A. Ingram has retired ... an ardent champion for innovation in the lifesciences industry, and ... Edwards, board as we pursue our focused innovation strategy," said ... has provided a valuable perspective to our board, drawing on ...
(Date:7/30/2015)... 2015  ResMed Inc. (NYSE: RMD ) today ...  Revenue for the quarter was $453.1 million, a 9 ... 2014 (a 17 percent increase on a constant currency ... quarter ended June 30, 2014.  Diluted earnings per share ... ended June 30, 2014.  The results ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... Oct. 26 Sequoia Pharmaceuticals presented,positive results today ... protease inhibitor (PI). One study based on an ... of SPI-256 with HIV protease,provides a rationale for ... The second study conducted in healthy volunteers demonstrates,that ...
... Results of two Phase III studies affirmed the ... 25 Data from two Phase III studies,showed ... painful effects,of rheumatoid arthritis (RA) achieved significant improvements ... alone or in combination,with methotrexate compared with methotrexate ...
Cached Medicine Technology:Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 2Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 3Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... five new industry players to know in predictive health analytics , Jvion ... learning technologies. The firm creates predictive software that targets patient and population level ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... communicate. Rally Insurance Group, Inc. has re-branded their social media profiles to better ... personal way for consumers to communicate, find information, share insights and opinions. The ...
(Date:7/31/2015)... ... , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection ... exam easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... 16 The non-profit,organization Women in Government presented ... Association today at the John F.,Kennedy Center for ... Pennsylvania and nine other states for launching a ... Lieutenant Governor Knoll accepted the award on behalf ...
... New Rankings Show No City Is Allergy-Free, WASHINGTON, Nov. ... this fall, and some cities are much worse than others,according ... Asthma and,Allergy Foundation of America (AAFA). The Foundation recently announced ... was,crowned "the most challenging place to live with fall allergies" ...
... Inc.,(Nasdaq: HOLX ), a diversified diagnostic and medical ... of women, today announced,the Company will host a meeting ... the RSNA (Radiological Society of North America) trade,show in ... November 27, 2007, at McCormick,Place from 8:00 - 10:00 ...
... /PRNewswire/ Dilon Technologies, Inc. a,United States manufacturer and ... of Scott Yarde for the position of,Vice President ... Yarde joins Dilon to provide leadership in national ... track record with 25,years of sales, marketing and ...
... to Impose Stiffer Penalties, ... State Investigators, CLAREMONT, Calif., Nov. 16 ... action lawsuit against Health Net,Life Insurance Company, alleging ... insurance policies has needlessly placed the,lives of hundreds ...
... at six sites nationwide , FRIDAY, Nov. 16 ... the genetic and environmental factors that may cause autism, ... 2,700 children and their families from six areas in ... Development -- which researchers called the largest of its ...
Cached Medicine News:Health News:Austin Named the New 'Fall Allergy Capital' 2Health News:Hologic, Inc. to Host Investor Reception at the RSNA Trade Show 2Health News:Dilon Technologies Appoints New VP of Sales & Business Development 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 3Health News:Major U.S. Autism Study Gets Under Way 2
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
For the quantitative determination of Gamma Glutamyltransferase in serum or plasma...
Medicine Products: